Home
About
FAQ
History (2)
IMP-3 is a novel progression marker in malignant melanoma.
Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 µg/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I).
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
IMP-3 is a novel progression marker in malignant melanoma.
Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 2008 Apr; 21(4):431-7.
View in:
PubMed
subject areas
Adolescent
Adult
Aged
Diagnosis, Differential
Disease Progression
Female
Humans
Immunohistochemistry
Male
Melanoma
Middle Aged
Neoplasm Proteins
Nevus
Precancerous Conditions
RNA-Binding Proteins
Skin Neoplasms
authors with profiles
Haodong Xu MD, PhD